As Alto Neuroscience’s machine learning-derived, biomarker-based depression therapies accrue positive phase 2 data, the company is planning to join the growing trickle of biotechs aiming to IPO in early 2024.

With the help of machine learning, scientists have identified a plethora of previously-unidentified drug targets for breast cancer, cervical cancer, glioblastoma and more.

In late November, ResMed issued a safety notice warning that some of the masks used with its CPAP machines contain magnets that could potentially interfere with pacemakers, neurostimulators and other implanted medical devices—an issue that has also plagued competitor Philips. In the weeks since, ResMed has upgraded the warning to a full-on field correction, which has in turn, like Philips’ own magnet-related safety event, earned the FDA’s most serious recall rating.

Illumina’s independently managed venture capital firm has opened up the doors to the new evolution of its startup incubator dubbed Illumina Ventures Labs.

Sometimes, you have to act while the tea is hot. For Roivant CEO Matt Gline, that meant dealing out Telavant to Roche for $7.1 billion last year, even if he wasn’t quite ready to let the vant company go.

The FDA has granted a de novo clearance to an artificial intelligence program capable of reading a standard brain MRI scan and predicting a patient’s chances of progressing from mild cognitive impairment and early memory loss to Alzheimer’s disease and dementia within five years, according to the software’s developer Darmiyan.

In mid-2021, after a decade of R&D, Neuralace Medical earned FDA clearance for its Axon Therapy, a noninvasive treatment option for chronic pain caused by nerve damage. The road to its next regulatory nod was much shorter: Less than three years later, the system now has a green light for use in treating nerve pain associated with diabetes, too.

Researchers have chipped away a little more at the mystery of cancer resistance, this time in the form of new findings that explain how the immune system senses DNA damage in precancerous cells.

Fortrea, the CRO that spun out of Labcorp last year, is linking up with trial software provider Veeva Systems and regulatory review company Advarra to leverage their services in an effort to streamline clinical trials.

CEO Stephen MacMillan took the microphone at the J.P. Morgan Healthcare Conference in San Francisco to describe “the new Hologic” in three words—a medtech company made “bigger, faster and stronger” in the wake of the COVID-19 pandemic.